Key facts
- Simbryo’s last known valuation is $19.0M (Nov 2025).
- It has raised $6.0M; the latest was Seed Round ($4.0M) in Nov 2025.
- Notable investors include Keyhorse Capital, Cintrifuse Capital, CUBIO Innovation Hub, Crown Ventures, TSV Capital (Los Altos).
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Simbryo
- ·The full record, as it builds
Funding rounds
No funding rounds for Simbryo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Simbryo
Operator of a commercial-stage biotech company intended to improve endometrial fertility and accelerate the path to pregnancy. The company offers organoid-based functional assays, AI-driven clinical insights, and a comprehensive endometrial test panel across inflammation, microbiome, pathology, and implantation timing, enabling fertility clinics and patients to understand reproductive health with greater clarity and make informed treatment decisions.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2023
- Employees
- 6
- Website
- simbryotech.com/
- Ownership
- Privately Held (backing)
Simbryo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Simbryo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Simbryo in its N-PORT filings yet. We sweep new filings monthly.